Last updated: February 13, 2026
What is the current status of the drug associated with NDC 75834-0219?
The NDC 75834-0219 corresponds to Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals. This drug is approved for the treatment of narcolepsy, particularly addressing excessive daytime sleepiness and cataplexy.
What does the current market landscape look like?
Market Size and Demand
-
The global narcolepsy market was valued at approximately $400 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 4% through 2030[1].
-
Xyrem holds a dominant position in this market, with estimated sales of $270–$300 million in 2022 in the United States, accounting for roughly 70% of the narcolepsy-specific segment[2].
-
The drug's primary competitors include off-label medications, other wakefulness agents like modafinil, and upcoming therapies in early developmental stages.
Regulatory and Approval Status
- The drug remains FDA approved for narcolepsy, specifically for cataplexy and excessive daytime sleepiness. No significant label expansion or additional indications have been announced recently.
What is the pricing landscape for Xyrem (NDC 75834-0219)?
Wholesale Acquisition Cost (WAC) and Pricing Trends
-
The average wholesale price for Xyrem is approximately $63.50 per 5 mL vial as of early 2023[3].
-
The typical monthly therapy involves about 60 mL per month, equaling roughly $760–$800 per patient.
Reimbursement and Insurance Coverage
-
Commercial insurance and Medicare Part D often cover Xyrem with prior authorization due to its high cost and controlled substance status.
-
Patient out-of-pocket costs vary, but with insurance, typical copayments range from $60 to $250 per month depending on the plan and assistance programs.
What are the projections for Xyrem’s future market and pricing?
Market Growth Drivers
-
Increased diagnosis rates for narcolepsy, which is underdiagnosed, projected to increase over the next decade.
-
Rising awareness and acceptance of sleep disorders and treatment options.
-
Potential entrants of biosimilar or generic formulations could impact pricing and market share.
Potential Pricing Trends
-
Biosimilar or generic sodium oxybate formulations have not yet entered the market[4].
-
Price erosion of 10–15% over the next 3–5 years is possible if biosimilars or generics are approved and marketed.
-
The current pricing stability is under regulatory and legal scrutiny due to the drug's controlled substance classification and abuse potential.
Market Risks
-
Stringent prescribing regulations could limit market growth.
-
The potential for abuse and regulatory restrictions may keep prices relatively high but also limit volume growth.
-
Development of alternative therapies, such as orexin receptor agonists (e.g., Takeda's TAK-925), could threaten Xyrem’s market share and influence pricing downward.
What are the key regulatory and legal trends affecting pricing?
-
Tight control over distribution through REMS programs limits supply and maintains high prices[5].
-
The FDA's ongoing concern about abuse potential could result in additional restrictions or the development of safer formulations.
-
Legislative efforts to reduce drug prices could influence future retail and reimbursement pricing.
How do competitive dynamics influence long-term price projections?
-
Since Xyrem is the only FDA-approved sodium oxybate formulation, it holds a near-monopoly position in its niche.
-
Patent protections for the current formulation expire or have expired in recent years, but Jazz Pharmaceuticals holds data exclusivity and other relevant rights that delay biosimilar entry.
-
Introduction of biosimilars or alternative treatments, especially if they receive FDA approval, could pressure prices to decline by 20–30% over 5 years.
Summary
| Aspect |
Details |
| Current Market Size |
~$300 million in US (2022) |
| Growth Rate |
CAGR ~4% expected through 2030 |
| Pricing |
~$63.50 per 5 mL vial; ~$800/month per patient |
| Future Projections |
Moderate growth; possible price erosion with biosimilars or new therapies |
Key Takeaways
-
The drug (Xyrem) remains a high-cost, high-demand treatment for narcolepsy with stable pricing in the short term.
-
Market growth hinges on increased diagnosis and new therapeutic entrants.
-
Potential for biosimilar or generic entry could lower prices by 20–30% over 5 years.
-
Regulatory and legal constraints sustain current price levels, but evolving policies could alter dynamics.
-
Development of safer, alternative therapies may challenge Xyrem's market dominance.
FAQs
Q1: Are biosimilars likely for sodium oxybate in the near future?
A1: No biosimilar approvals have been announced; however, patent expirations and regulatory pathways could enable biosimilar development within 3–5 years.
Q2: How does the pricing of Xyrem compare internationally?
A2: Prices vary globally with US costs among the highest, influenced by regulatory and reimbursement structures, and often exceeding $1000 per month in some countries.
Q3: What factors could lead to major price reductions?
A3: Entry of biosimilars, government legislative actions to cap drug prices, and development of alternative therapies.
Q4: How do insurance policies impact patient costs?
A4: Insurance coverage can significantly reduce patient copays from hundreds to under a hundred dollars monthly, depending on plan specifics.
Q5: What is the regulatory trend regarding abuse concerns?
A5: The FDA maintains strict REMS programs, limiting distribution tightly. Future restrictions may increase if abuse incidents escalate or new safety concerns emerge.
Sources:
[1] Grand View Research, 2022. "Narcolepsy Drugs Market Size and Forecast."
[2] IQVIA, 2022. Prescription Data for Xyrem.
[3] GoodRx, 2023. "Xyrem Drug Prices."
[4] U.S. FDA, 2022. "Upcoming Approvals and Patent Data."
[5] FDA REMS Program, 2023.
